Lenox Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lenox Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$4K	Sell	49 -7	-13%	-$586	﹤0.01%	577
2021 Q4	$5K	Buy	56 +7	+14%	+$578	﹤0.01%	596
2021 Q3	$4K	Hold	49	–	–	﹤0.01%	573
2021 Q2	$4K	Hold	49	–	–	﹤0.01%	579
2021 Q1	$4K	Hold	49	–	–	﹤0.01%	528
2020 Q4	$4K	Hold	49	–	–	﹤0.01%	526
2020 Q3	$4K	Hold	49	–	–	﹤0.01%	452
2020 Q2	$6K	Hold	49	–	–	﹤0.01%	413
2020 Q1	$4K	Hold	49	–	–	﹤0.01%	444
2019 Q4	$4K	Hold	49	–	–	﹤0.01%	496
2019 Q3	$3K	Hold	49	–	–	﹤0.01%	442
2019 Q2	$4K	Hold	49	–	–	﹤0.01%	324
2019 Q1	$4K	Hold	49	–	–	﹤0.01%	389
2018 Q4	$4K	Hold	49	–	–	﹤0.01%	295
2018 Q3	$5K	Hold	49	–	–	﹤0.01%	306
2018 Q2	$5K	Hold	49	–	–	﹤0.01%	451
2018 Q1	$4K	Buy	+49	New	+$4.21K	﹤0.01%	429

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lenox Wealth Advisors's BMRN Position: Q1 2022 in Review

Lenox Wealth Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q1 2022, selling an estimated $586 and leaving 49 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #577.

Lenox Wealth Advisors first reported a position in BMRN in Q1 2018 and has held it in 17 quarters since. The position peaked at $6K in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Lenox Wealth Advisors held 49 shares of BioMarin Pharmaceuticals worth $4K as of Q1 2022.
Lenox Wealth Advisors sold 7 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $586.
BioMarin Pharmaceuticals made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #577 holding.
Lenox Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 17 quarters since.
Lenox Wealth Advisors's BioMarin Pharmaceuticals position peaked at $6K in Q2 2020.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.